## 4 Conclusions  
In conclusion, for the three analyzed techniques, the flavone type analogs showed a better antioxidant profile when compared to the chalcones, however this does not mean that the latter were inactive since many of them resulted highly active. Surprisingly, the compounds **2j, 2k, 3j**, and **3k** presented a high potential as antioxidant agents, this could be due to the quinone and oxyfuranone type products that are generated after their oxidation. As previous reports have stated, the presence of hydroxyl groups favors the antiradical activity mediated by hydrogen donation, as it could be noticed that compounds **2b** and **3b** surpassed the positive controls in both DPPH and ABTS assays; in the \(\beta\)-carotene technique, the electron-donor substitutions were the most active.  
On the other hand, in the AChE inhibition assay, the better results from the chalcone and flavone families (compounds **2d** and **3d**) share the nitro functional group, with IC\({}_{50}\) values of 21.5 and 26.8 \(\mu\)g/mL, respectively. The docking results suggest that the principal interactions compounds **2d** and **3d** have with AChE active site are mostly \(\pi\)-\(\pi\) stackings. This can be observed with residues Trp84 and Tyr334 from the CAS and PAS, which are known binding zones of the enzyme.  
Although further in vivo testing must be performed, our results represent an important step towards the identification of improved antioxidants and acetylcholinesterase inhibitors.  
The following are available online at [[http://www.mdpi.com/2076-3417/9/3/410/s1](http://www.mdpi.com/2076-3417/9/3/410/s1)]([http://www.mdpi.com/2076-3417/9/3/410/s1](http://www.mdpi.com/2076-3417/9/3/410/s1)), Figure S1: \({}^{1}\)H-NMR Compound **2e**, Figure S2: \({}^{13}\)C-NMR Compound **2e**, Figure S3: COSY-Compound **2e**, Figure S4: HSQC-Compound **2e**, Figure S5: HMPC-Compound **2e**, Figure S6: \({}^{1}\)H-NMR Compound **3e**, Figure S7: \({}^{13}\)C-NMR Compound **3e**, Figure S8: COSY Compound **3e**, Figure S9: HSQC Compound **3e**, Figure S10: HMPC Compound **3e**, Figure S11: \({}^{1}\)H-NMR Compound **2k**, Figure S12: \({}^{13}\)C-NMR Compound **2k**, Figure S13: \({}^{1}\)H-NMR Compound **3k**, Figure S14: \({}^{13}\)C-NMR Compound **3k**, Figure S15: \({}^{1}\)H-NMR Compound **2h**, Figure S16: \({}^{13}\)C-NMR Compound **2h**, Figure S17: \({}^{1}\)H-NMR Compound **3h**, Figure S18: \({}^{13}\)C-NMR Compound **3h**, Figure S19: \({}^{1}\)H-NMR Compound **2d**, Figure S20: \({}^{13}\)C-NMR Compound **2d**, Figure S21: \({}^{1}\)H-NMR Compound **2j**, Figure S22: \({}^{13}\)C-NMR Compound **2j**, Figure S23: \({}^{1}\)H-NMR Compound **3j**, Figure S24: \({}^{13}\)C-NMR Compound **3j**.  
Conceptualization, [PERSON] supervised the whole study; [PERSON] and [PERSON] carried out the chemical synthesis; [PERSON] and [PERSON] performed the chemical assay, [PERSON] and [PERSON] performed the spectroscopic data; [PERSON] collaborated in the discussion and interpretation of the results; [PERSON], [PERSON] and [PERSON] wrote the manuscript; [PERSON] and [PERSON] performed the enzymatic assay; [PERSON] and [PERSON] carried out the silico study. All authors read and approved the final manuscript.  
We gratefully acknowledge the Facultad de Ciencias Quimicas e Ingenieria, Universidad Autonoma de Baja California for the financing given for the realization of this project. Additionally, to the Consejo Nacional de Ciencia y Tecnologia (CONACYT) for ITT NMR facilities (Grant INFR-2011-3-173395).  
The authors declare no conflict of interest.